Advancing new medicines to benefit patients with viral-associated cancers and other serious diseases.

Viracta is a clinical-stage precision oncology company targeting virus-associated cancers, focused on advancing a proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr Virus (EBV), and will pursue opportunities to address other serious virus-associated diseases. The Company's proprietary investigational drug, Nanatinostat, is currently being evaluated in combination with the antiviral agent Valganciclovir as an oral combination therapy in a registrational clinical trial for EBV-positive lymphomas.